Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Icos discontinues Phase III of LeukArrest

ICOS said that results from an interim analysis of its Phase III trial of LeukArrest to treat ischemic stroke "failed to meet the company's predefined criteria

Read the full 269 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE